(Q46406749)

21 December 2017

http://europepmc.org/abstract/MED/24684973

title

Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom (English)

1 reference

21 December 2017

http://europepmc.org/abstract/MED/24684973

0 references

Mark Agius

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

Xiangyi Meng

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

Peter Chin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

Augusto Grinspan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

Ronny Hashmonay

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

publication date

31 March 2014

1 reference

21 December 2017

http://europepmc.org/abstract/MED/24684973

published in

CNS Neuroscience & Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

page(s)

446-451

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

14 May 2020

cites work

1 reference

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

Impact of multiple sclerosis relapses on progression diminishes with time

21 January 2018

1 reference

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

21 January 2018

1 reference

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

21 January 2018

1 reference

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

21 January 2018

1 reference

Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence.

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

Epitope spreading in immune-mediated diseases: implications for immunotherapy

21 January 2018

1 reference

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

Relapses in multiple sclerosis are age- and time-dependent

21 January 2018

1 reference

Functional role of epitope spreading in the chronic pathogenesis of autoimmune and virus-induced demyelinating diseases.

21 January 2018

1 reference

12 December 2020

Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis

1 reference

12 December 2020

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

12 December 2020

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Identifiers

DOI

10.1111/CNS.12235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493139&resulttype=core&format=json

14 May 2020

1 reference